Moelis & Company Announces the Appointment of Maarten de Jong as a Managing Director Providing Financial and Strategic Advice to Healthcare Clients

New York, May 20, 2014

Moelis & Company (NYSE: MC), a leading global independent investment bank, today announced the appointment of Maarten de Jong as a Managing Director providing financial and strategic advice to healthcare clients in the U.S. and internationally. Mr. de Jong will join the Firm in August and will be based in New York.

Mr. de Jong brings nearly 20 years of experience to Moelis & Company having previously worked at Barclays Capital, and formerly Lehman Brothers, where he was most recently Global Head of Life Sciences. At Barclays, he focused on pharmaceuticals, biotechnology and diagnostics, and developed a portfolio of relationships across the U.S. and Europe.

Rick Leaman, Managing Partner of Moelis & Company, said, “With the continued high level of activity in the healthcare sector, Maarten’s appointment, which enhances our existing global healthcare franchise, makes us well positioned to advise clients on their strategic and financial initiatives.”

Mr. Leaman added, “We will continue to see pharmaceutical companies re-aligning their asset portfolios by separating their non-core businesses while also investing further in the growth of their core businesses. This, together with the maturation of the large biotechnology companies, will continue to drive strategic momentum in the broader Life Sciences arena.”

About Moelis & Company
Moelis & Company is a leading global independent investment bank that provides innovative strategic advice and solutions to a diverse client base, including corporations, governments and financial sponsors.  The Firm assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across all major industry sectors.  Moelis & Company’s experienced professionals advise clients on their most critical decisions, including mergers and acquisitions, recapitalizations and restructurings and other corporate finance matters.  The Firm serves its clients with nearly 500 employees based in 15 offices in North and South America, Europe, the Middle East, Asia and Australia. For further information, please visit: